Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Trial Details

NCT ID
NCT06257693
Phase
PHASE1
Sponsor
Alessa Therapeutics Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • enzalutamide
Locations (sample)
  • Fresno, California, United States|36.74773,-119.77237
  • San Francisco, California, United States|37.77493,-122.41942
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Metairie, Louisiana, United States|29.98409,-90.15285
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Age at least 21 years old
  • Histologically confirmed adenocarcinoma of the prostate
  • Study participant qualified and planning for radical prostatectomy
  • At least 1 prostate lesion measurable by MRI greater or equal to 0.5 cm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →